Literature DB >> 3818977

Factor II, VII, IX and X concentrations in patients receiving long term warfarin.

B Paul, A Oxley, K Brigham, T Cox, P J Hamilton.   

Abstract

Using standard one stage clotting assays the concentrations of factors II, VII, IX and X were determined in 37 patients stabilised on warfarin for between three months and 17 years. Contrary to popular belief, the concentrations were not equally depressed, with factor X the lowest, factor II at intermediate value, factors VII and IX the highest. Some 71% of the variance of the British corrected ratio (BCR) could be accounted for by measurement of the factors assayed. Analysis of this variance showed 91% of the explained variance attributable to factor II, 7% to factor VII, 1.6% to factor IX and 0.4% to factor X. With the sudden and recent withdrawal of human thromboplastin, investigation of the sensitivities of the animal thromboplastins to changes in vitamin K dependent factors in orally anticoagulated patients is needed to ensure that the potentially alarming falls in factors II and X in these patients are being adequately detected.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3818977      PMCID: PMC1140836          DOI: 10.1136/jcp.40.1.94

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  EFFECT OF ORAL ANTICOAGULANTS ON FACTORS VII, IX, X, AND II.

Authors:  F KAZMIER; J A SPITTELL; J J THOMPSON; C A OWEN
Journal:  Arch Intern Med       Date:  1965-06

2.  Standardization of laboratory tests for controlling anticoagulent therapy.

Authors:  S Zucker; M H Cathey; P J Sox; E C Hall
Journal:  Am J Clin Pathol       Date:  1970-03       Impact factor: 2.493

3.  An evaluation of chromogenic substrates in the control of oral anticoagulant therapy.

Authors:  Z S Latallo; J M Thomson; L Poller
Journal:  Br J Haematol       Date:  1981-02       Impact factor: 6.998

4.  Evaluation of an automated prothrombin assay using a chromogenic substrate.

Authors:  J A Conkie; F McCall; I D Walker; J F Davidson
Journal:  Haemostasis       Date:  1984

Review 5.  Oral anticoagulants.

Authors:  J H Winter; A S Douglas
Journal:  Clin Haematol       Date:  1981-06
  5 in total
  7 in total

1.  Factors II, VII, IX, and X concentrations in patients receiving long term treatment with warfarin.

Authors:  G Evans; M Wickham; M Bhavnani
Journal:  J Clin Pathol       Date:  1987-08       Impact factor: 3.411

2.  Direct oral anticoagulants in factor VII deficiency patient.

Authors:  Fulvio Pomero; Laura Spadafora; Salvatore D'Agnano; Francesco Dentali; Luigi Maria Fenoglio
Journal:  Intern Emerg Med       Date:  2019-09-16       Impact factor: 3.397

Review 3.  Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.

Authors:  G Palareti; C Legnani
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 4.  Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy.

Authors:  Takeshi Omae; Keito Koh; Masateru Kumemura; Sonoko Sakuraba; Yosuke Katsuda
Journal:  J Anesth       Date:  2019-05-08       Impact factor: 2.078

5.  The anticoagulant, antithrombotic and haemorrhagic effect of long-term warfarin on experimental venous and arterial thrombosis in the rat.

Authors:  M MacIomhair; S M Lavelle
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

6.  Anticoagulation Therapy Considerations in Factor VII Deficiency.

Authors:  Eric Paulus; Kathy Komperda; Gabriel Park; Julie Fusco
Journal:  Drug Saf Case Rep       Date:  2016-12

7.  A factor VII-based method for the prediction of anticoagulant response to warfarin.

Authors:  Qing-Xi Ooi; Daniel F B Wright; Geoffrey K Isbister; Stephen B Duffull
Journal:  Sci Rep       Date:  2018-08-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.